ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
C4 Therapeutics Inc

C4 Therapeutics Inc (CCCC)

8.05
0.11
(1.39%)
Closed March 27 04:00PM
8.05
0.00
( 0.00% )
Pre Market: 04:44AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
8.05
Bid
8.08
Ask
8.20
Volume
2
0.00 Day's Range 0.00
1.06 52 Week Range 11.88
Market Cap
Previous Close
8.05
Open
-
Last Trade
1
@
8.16
Last Trade Time
05:13:19
Financial Volume
-
VWAP
-
Average Volume (3m)
4,125,140
Shares Outstanding
68,600,669
Dividend Yield
-
PE Ratio
-4.17
Earnings Per Share (EPS)
-1.93
Revenue
20.76M
Net Profit
-132.49M

About C4 Therapeutics Inc

C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
C4 Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CCCC. The last closing price for C4 Therapeutics was $8.05. Over the last year, C4 Therapeutics shares have traded in a share price range of $ 1.06 to $ 11.88.

C4 Therapeutics currently has 68,600,669 shares outstanding. The market capitalization of C4 Therapeutics is $552.24 million. C4 Therapeutics has a price to earnings ratio (PE ratio) of -4.17.

CCCC Latest News

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 8-K - Current report

0001662579false00016625792024-03-082024-03-08UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549_________________________________________________________________FORM...

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...

Form 8-K - Current report

0001662579false00016625792024-03-042024-03-04UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549_________________________________________________________________FORM...

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery...

Form S-8 - Securities to be offered to employees in employee benefit plans

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_____________________________________FORM S-8REGISTRATION STATEMENTUnder The Securities Act of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.81-9.142212189628.869.1857.7615076778.20940545CS
4-3.08-27.672955974811.1311.887.7627296529.63425408CS
122.1235.75042158525.9311.88541251407.62940118CS
266.24344.7513812151.8111.881.0683221985.18538532CS
524.63135.3801169593.4211.881.0645522675.00166511CS
156-28.93-78.231476473836.9851.211.0618647597.54518042CS
260-18.55-69.736842105326.651.211.0616657418.3833044CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 16.44
(246.11%)
338.8k
BCGBinah Capital Group Inc
$ 21.50
(126.32%)
87.61k
PIKKidpik Corporation
$ 5.55
(69.72%)
628.04k
SSKNStrata Skin Sciences Inc
$ 0.66
(48.35%)
2
KTRAKintara Therapeutics Inc
$ 0.118
(31.84%)
7.45M
WAVDWaveDancer Inc
$ 2.93
(-18.61%)
10
UGROUrban Gro Inc
$ 1.48
(-18.46%)
393
INOInovio Pharmaceuticals Inc New
$ 10.65
(-18.27%)
33
SOBRSOBR Safe Inc
$ 0.41
(-18.00%)
1.49k
MVLAMovella Holdings Inc
$ 0.0624
(-17.35%)
9.9k
KTRAKintara Therapeutics Inc
$ 0.1181
(31.96%)
7.47M
AKBAAkebia Therapeutics Inc
$ 2.79
(24.55%)
1.99M
CISSC3is Inc
$ 0.0352
(-7.85%)
1.06M
GMDAGamida Cell Ltd
$ 0.0506
(-14.53%)
1.02M
VERBVerb Technology Company Inc
$ 0.2715
(-3.38%)
630.97k

CCCC Discussion

View Posts
B RY B RY 1 day ago
C4 is still the one, lol.
👍️0
looking 4 a win looking 4 a win 2 days ago
I love the classics, and the meaning.
👍️0
looking 4 a win looking 4 a win 1 week ago
I’ve been a passive investor for about 13 years not spending a lot of time/money into it. Since I lost job I’m borderline obsessive about every tick. This really needs to go up. I know I know why this is a bad idea while I look for a job, but I allowed myself to get excited and you never trade with emotion.

C4!
👍️0
looking 4 a win looking 4 a win 1 week ago
This is great thanks!
👍️0
B RY B RY 1 week ago
"Combined with savings from the layoffs and restructured operations, C4 said it now expects its cash runway to extend into 2027.

The decision to restructure the company “was not a decision we made lightly,” CEO Andrew Hirsch said in the Jan. 9 release.

“Our sharpened focus on progressing CFT7455 and CFT1946 to critical clinical milestones, along with advancing targeted protein degradation research through our discovery collaborations with Roche, Biogen and Merck and our internal research efforts, will help C4T deliver breakthrough therapies for patients with cancer and other diseases,” Hirsch added."

I don't care much for press releases alone. I like to research company operations to see if they are truly attempting to create a strong future. I've found Fierce biotech to be a good source of articles on pharmaceutical companies operations for quick research. There are many others for indepth research when time permits.

https://www.fiercebiotech.com/biotech/moderna-says-it-wont-advance-us-backed-zika-vaccine-without-more-outside-funding
👍️0
looking 4 a win looking 4 a win 1 week ago
I’m just glad you said has instead of had. It’s been so long since I’ve made any money I’m just excited to see green. I do know pigs get slaughtered so I’ll control my greed, lol.
👍️0
B RY B RY 2 weeks ago
"The share price as of March 15, 2024 is 8.93 / share. Previously, on March 17, 2023, the share price was 3.93 / share. This represents an increase of 127.23% over that period."

I mainly posted this to help keep proper perspective of C4 in light of it's recent slide. C4 is simply a pharma stock I believe has really good upside. Imo, pharma's are notoriously shorted by competitors who well understand their business cycle and competitive environment. I'm not interested in making any predictions. I simply enjoy researching and like what I see in C4's future. Glta!
👍️0
B RY B RY 2 weeks ago


https://fintel.io/so/us/cccc
👍️0
looking 4 a win looking 4 a win 2 weeks ago
This is crazy, I’m adding.
👍️0
B RY B RY 2 weeks ago
Exactly! Short positions executing, bfd...lol.
👍️0
kindo kindo 2 weeks ago
I don’t see any bad news so I’d agree with healthy pullback.
👍️0
looking 4 a win looking 4 a win 2 weeks ago
Any thoughts on today’s drop? Healthy pull back? Sell on news?
👍️0
looking 4 a win looking 4 a win 2 weeks ago

C4 Therapeutics announces strategic discovery research collaboration with Merck (MRK) KGaA, Darmstadt, Germany, against critical oncogenic proteins
Under the terms of the agreement, C4T and Merck KGaA, Darmstadt, Germany, will collaborate to discover two targeted protein degraders against critical oncogenic proteins. C4T will receive an upfront payment of $16 mln. Merck KGaA Darmstadt, Germany, will fund C4T''s discovery research efforts. C4T has the potential to receive up to approximately $740 mln in discovery, regulatory, and commercial milestone payments across the collaboration. In addition, C4T is eligible for mid-single to low-double digit tiered royalties on future sales for each program.
As part of the collaboration, C4T will utilize its proprietary TORPEDO platform to discover degraders targeting the partnership''s oncogenic proteins of interest. Merck KGaA, Darmstadt, Germany, will be responsible for clinical development and commercialization for drug candidates coming out of these programs.

What does “min” mean?
👍️0
looking 4 a win looking 4 a win 2 weeks ago
Just can’t seem to break and hold $11, oh well it’s cool, more time to add.
👍️0
looking 4 a win looking 4 a win 3 weeks ago
Good point!
👍️0
B RY B RY 3 weeks ago
We like crickets, lol. Stock does talking.
👍️0
looking 4 a win looking 4 a win 3 weeks ago
Looks like consolidation and trying to decide which way to go. Up baby!
👍️0
looking 4 a win looking 4 a win 3 weeks ago
Surprised at how quiet the board is. I’m hoping for sell on news then moon rocket.
👍️0
looking 4 a win looking 4 a win 3 weeks ago
Read the whole thing and I don’t understand. I think it’s good though.
👍️0
subslover subslover 3 weeks ago
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline

C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research Costs Under the Collaboration

C4T Eligible for up to Approximately $740 Million in Discovery, Development and Commercial Milestone Payments, in Addition to Future Royalties, Across Entire Collaboration

WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has entered into a license and collaboration agreement with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline.

“We look forward to partnering with Merck KGaA, Darmstadt, Germany, and leveraging our collective strengths to advance an exciting program from C4T’s internal oncology pipeline that has the potential to transform how cancer is treated,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “This new partnership highlights C4T’s differentiated approach to targeted protein degradation science and our strong track record of designing novel targeted protein degrader medicines with desirable drug-like properties that have the potential to treat patients with unmet medical needs.”

“The collaboration adds to Merck KGaA, Darmstadt, Germany's growing portfolio of targeted protein degradation projects and accelerates our efforts to expand our presence in this highly dynamic field,” said Paul Lyne, Head of Research Unit Oncology at the Healthcare business sector of Merck KGaA, Darmstadt, Germany. “We look forward to capitalizing on C4 Therapeutics’ experience in advancing degrader candidates targeting disease-causing proteins from discovery to the clinical stage, with the shared goal of improving patient outcomes.”

Under the terms of the agreement, C4T and Merck KGaA, Darmstadt, Germany, will collaborate to discover two targeted protein degraders against critical oncogenic proteins. C4T will receive an upfront payment of $16 million. Merck KGaA Darmstadt, Germany, will fund C4T’s discovery research efforts. C4T has the potential to receive up to approximately $740 million in discovery, regulatory, and commercial milestone payments across the collaboration. In addition, C4T is eligible for mid-single to low-double digit tiered royalties on future sales for each program.

As part of the collaboration, C4T will utilize its proprietary TORPEDO® platform to discover degraders targeting the partnership’s oncogenic proteins of interest. Merck KGaA, Darmstadt, Germany, will be responsible for clinical development and commercialization for drug candidates coming out of these programs.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Forward-Looking Statements
This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders; our ability to achieve potential future milestone or royalty payments; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ
👍️0
looking 4 a win looking 4 a win 4 weeks ago
Good thinking
👍️0
kindo kindo 4 weeks ago
I’m just going to continue to accumulate because I think there are many catalysts on the near horizon.
I’m not a chartist but with all the institutional buying that it bodes well for the future here.
Not saying that somewhere down the road if it really took off that I wouldn’t take some off the table.
👍️0
looking 4 a win looking 4 a win 4 weeks ago
Screw it, I don’t want to chance it running and not having a ticket. All in all
👍️0
looking 4 a win looking 4 a win 4 weeks ago
Gave myself a little haircut this morning to let the RSI cool off a little bit. I’m thinking $9 might be time to jump back in.
👍️0
subslover subslover 4 weeks ago
$11.37 HOD + another 52 week high
👍️0
looking 4 a win looking 4 a win 4 weeks ago
HA! The wife watches enough crime tv that she’d probably get away with it.
👍️0
subslover subslover 4 weeks ago
LMFAO. Bob just told me that we broke $10.00 and that If five gets ya ten, ten'll get ya twenty. A beautiful home in the country, upstairs and down. Beer flowing through the estate over your grandmother's paisley shawl. Fishing in the stream that runs under the aboreal dell. A man comes up from the bar, dumps $3,500 in your lap for every nickel invested. Says to you, "Sign here on the dotted line." And then disappears in the waving fields of alfalfa.
👍️0
B RY B RY 1 month ago
Unless you're bob. Another nice day.
👍️0
Monksdream Monksdream 1 month ago
CCCC new 52 week high
👍️0
kindo kindo 1 month ago
This may be a good stock to just keep accumulating and in a few years be sitting on a $100 stock.
👍️0
looking 4 a win looking 4 a win 1 month ago
Nice day
👍️0
subslover subslover 1 month ago
52-week high smashed! :)
👍️0
subslover subslover 1 month ago
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024

Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; Data from Both Trials Expected in 2H 2024

Well Capitalized with Cash Runway Expected into 2027

WATERTOWN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended December 31, 2023, as well as recent business updates.

“2023 was an important year for C4T as we executed across three clinical trials, entered into two new collaborations, generated positive dose escalation data from our CFT7455 program for patients with relapsed/refractory multiple myeloma, and meaningfully extended our cash runway,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “We began 2024 with positive momentum across our portfolio and are looking forward to sharing data from our two lead programs, CFT7455 and CFT1946, in the second half of the year, as well as supporting our partner, Betta Pharmaceuticals, with trial start-up activities for the Phase 1 trial of CFT8919 in Greater China this year. As we continue to advance our portfolio, we are well-positioned with a strong balance sheet to deliver on our goals and execute through and beyond meaningful value inflection points in order to bring new therapeutic options to patients with difficult-to-treat diseases.”

FOURTH QUARTER 2023 AND RECENT ACHIEVEMENTS

CFT7455: CFT7455 is an oral degrader of IKZF1/3 for the potential treatment of relapsed/refractory (R/R) multiple myeloma (MM) and R/R non-Hodgkin’s lymphomas (NHL).

Presented Positive Data from the Ongoing Phase 1/2 Trial in R/R MM. In December 2023, presented positive clinical data from the ongoing CFT7455 Phase 1/2 trial in R/R MM showing that the 14 days on/14 days off schedule is optimal. Additionally, the data demonstrated anti-myeloma activity, including International Myeloma Working Group (IMWG) responses in patients who have undergone numerous lines of prior therapy for MM, including BCMA therapies.
Advanced the Phase 1/2 Clinical Trials. The dose escalation portion of the Phase 1/2 trials evaluating CFT7455 in combination with dexamethasone for R/R MM and as a monotherapy for R/R NHL continues to progress. As of February 2024, two dose levels are open for enrollment in the Phase 1/2 trial for R/R MM and one dose level open for enrollment in the Phase 1/2 trial for R/R NHL.
CFT1946: CFT1946 is an oral degrader targeting BRAF V600X mutations for the potential treatment of solid tumors including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and melanoma.

Shared Encouraging Initial Pharmacokinetic (PK) and Pharmacodynamic (PD) Data. In January 2024, shared PK and PD data from the initial escalation cohorts of the CFT1946 Phase 1/2 trial demonstrating dose proportional exposure and oral bioavailability, which are associated with deep degradation of BRAF V600E, a clinically validated target.
New Preclinical Data Accepted as a Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024. Accepted to present CFT1946 preclinical data demonstrating differentiated activity in preclinical models of BRAF V600X melanoma, CRC, NSCLC and brain metastasis.
Advanced the Phase 1/2 Clinical Trial. The dose escalation portion of the CFT1946 Phase 1/2 trial for BRAF V600X mutations, including NSCLC, CRC and melanoma, continues to progress. As of February 2024, three escalation cohorts are complete and dose escalation continues with a fourth dose level currently enrolling.
Collaborations:

Merck

In December 2023, C4T and Merck entered into a license and research collaboration to discover and develop degrader antibody conjugates. Under the terms of the agreement, C4T and Merck will collaborate to develop degrader antibody conjugates directed to an initial undisclosed oncology target exclusive to the collaboration; in January 2024, C4T received the $10 million upfront payment for this initial target. C4T is eligible to receive milestone payments totaling approximately $600 million, as well as tiered royalties on future sales, for degrader antibody conjugates directed to this initial target. The agreement also provides Merck with the option to extend the collaboration to include three additional targets that would be exclusive to the collaboration, which could yield option exercise payments as well as potential milestones and royalties. If Merck exercises all of its options to extend the collaboration, C4T would be eligible to receive up to approximately $2.5 billion in potential payments across the entire collaboration.
Betta Pharmaceuticals

In January 2024, the previously announced $25 million stock purchase by a subsidiary of partner Betta Pharmaceuticals was completed.
In December 2023, Betta Pharmaceuticals received approval from the Chinese National Medical Products Administration for the Clinical Trial Application of CFT8919, which is being evaluated in patients with EGFR L858R NSCLC.
Corporate Updates:

In January 2024, C4T announced 2024 strategic priorities focused on advancing product candidates CFT7455 and CFT1946, delivering on discovery collaborations, and streamlined internal research efforts, which resulted in an approximately 30% reduction in the company’s workforce.
As announced in January 2024, C4T sold approximately 13.7 million shares under the company’s at the market (ATM) offering arrangement, at an average price of $5.42 per share, resulting in approximately $72 million of new equity capital, net of commissions and fees. As of December 31, 2023, 11.2 million of these shares had settled for net proceeds of $57.7 million.
In November 2023, C4T appointed Owen Hughes to its board of directors. Mr. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance.
KEY UPCOMING MILESTONES

CFT7455:

Present updated data from the ongoing Phase 1 dose escalation trial in R/R MM in 2H 2024.
Present data from the ongoing Phase 1 dose escalation trial in R/R NHL in 2H 2024.
Complete Phase 1 dose exploration in R/R MM and R/R NHL by year-end 2024.
CFT1946:

Present preclinical data demonstrating differentiated activity in preclinical models of BRAF V600X NSCLC, CRC, melanoma and brain metastasis at the AACR Annual Meeting taking place April 5 – 10, 2024 in San Diego, CA.
Present clinical data from the ongoing Phase 1 dose escalation trial in NSCLC, CRC, melanoma and other cancers with BRAF V600X mutations in 2H 2024.
UPCOMING INVESTOR EVENTS

March 4, 2024: Management will present at TD Cowen’s 44th Annual Health Care Conference taking place March 4 - 6, 2024, at the Marriott Copley Place in Boston, MA.
March 11, 2024: Management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference taking place March 11 - 13, 2024, at the Fontainebleau in Miami, FL.
FULL YEAR 2023 FINANCIAL RESULTS

Revenue: Total revenue for the year ended December 31, 2023 was $20.8 million, compared to $31.1 million for the year ended December 31, 2022. The decrease in revenue was primarily due to the collaboration agreement with Calico ending in January 2023 and completion of research activities for a target under the collaboration agreement with Biogen, partially offset by the completion of research activities for select targets under the collaboration agreement with Roche. 2023 revenue reflects amounts recognized under our collaboration agreements with Biogen, Calico, and Roche.

Research and Development (R&D) Expense: R&D expense for the year ended December 31, 2023 was $117.7 million, compared to $117.8 million for the year ended December 31, 2022. R&D expense was relatively flat year over year as preclinical costs decreased and clinical costs increased with the transition of CFT1946 to clinical development.

General and Administrative (G&A) Expense: G&A expense for the year ended December 31, 2023 was $42.1 million, compared to $42.8 million for the year ended December 31, 2022. The decrease in G&A expense was primarily attributable to a decrease in professional fees.

Net Loss and Net Loss per Share: Net loss for the year ended December 31, 2023 was $132.5 million, compared to $128.2 million for the year ended December 31, 2022. Net loss per share for the year ended December 31, 2023 was $2.67, compared to $2.62 for the year ended December 31, 2022.

Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of December 31, 2023 were $281.7 million, compared to $337.1 million as of December 31, 2022. Cash and cash equivalents as of December 31, 2023 do not include $25 million in proceeds from the sale of shares of our common stock to a subsidiary of Betta Pharmaceuticals, $14.1 million of proceeds in connection with the settlement of 2,500,601 shares under our ATM program, and the $10.0 million upfront payment related to our collaboration agreement with Merck, all of which were received in January 2024. The company expects that its cash, cash equivalents and marketable securities as of December 31, 2023, together with these amounts received in January 2024, which result in a proforma balance of approximately $330 million, will enable the company to fund its operating plan into 2027.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

About CFT7455
CFT7455 is an orally bioavailable MonoDAC™ degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3) and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). CFT7455 is currently in a Phase 1 dose escalation study in MM and NHL. Initial clinical data show CFT7455 is well tolerated, demonstrates anti-myeloma activity and displays evidence of immunomodulatory effects. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).

About CFT1946
CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E-driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600 mutant solid tumors including non-small cell lung cancer, colorectal cancer and melanoma. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585).

About CFT8919
CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in in vitro and in vivo models of L858R driven non-small cell lung cancer. Importantly, in preclinical studies, CFT8919 retains full activity against additional EGFR mutations that confer resistance against approved EGFR inhibitors including L858R-C797S, L858R-T790M and L858R-T790M-C797S. In 2023, C4T and Betta Pharmaceuticals entered into an exclusive licensing and collaboration agreement for the development and commercialization of CFT8919 in Greater China, including Hong Kong SAR, Macau SAR and Taiwan.

Forward-Looking Statements
👍️0
subslover subslover 1 month ago
Nice to see us trading into the 8's again! :)
👍️0
looking 4 a win looking 4 a win 1 month ago
I knew I should’ve bought more a couple weeks ago. Nice to see green.
👍️0
TheFinalCD TheFinalCD 1 month ago
I MISSED THIS , THANKS FOR THE HEADS UP

https://fintel.io/so/us/cccc
👍️0
subslover subslover 1 month ago
Several mega giant institutions filed for over 5% ownership today. That must have scared a few shorts to cover. Still a large % shorts in stock.
👍️0
B RY B RY 2 months ago
100% agree and thank you for awareness.
👍️0
looking 4 a win looking 4 a win 2 months ago
I have donated to the Toby Kieth foundation for children in the past, it’s a great charity. He’s been helping children for years and I hope this tragedy brings more awareness to kids in need.
👍️0
looking 4 a win looking 4 a win 2 months ago
100% agree, gone way too soon and a amazing talent and human being.
👍️0
B RY B RY 2 months ago
While C4 is still at this level, I dedicate this reasonable price to toby keith...lord rest his soul.
👍️0
B RY B RY 2 months ago
JP has jan 29 upgrade/neutral rating.https://finviz.com/quote.ashx?t=CCCC&p=d
👍️0
looking 4 a win looking 4 a win 2 months ago
How are feeling for the upcoming week?
👍️0
B RY B RY 2 months ago
Cccc...right on!
👍️0
looking 4 a win looking 4 a win 2 months ago
We’ve got a Burna-Doddle and she’s the best!
👍️0
B RY B RY 2 months ago
CCCC understands...
👍️0
looking 4 a win looking 4 a win 2 months ago
I’ve waiting for the right time to jump in, I think this maybe it.

???
👍️0
subslover subslover 2 months ago
She was beautiful. :) Dogs and Cats are unconditional love!
👍️0
B RY B RY 2 months ago
Nope, but this was my husky. She passed away in 2012.
👍️0
subslover subslover 2 months ago
OMG! What a gorgeous kitty! Is that your cat buddy?
👍️0

Your Recent History

Delayed Upgrade Clock